The Use of Heparin for Treating Human Malignancies

Publisher： Karger

E-ISSN： 1424-8840|29|1|48-60

ISSN： 1424-8832

Source： Pathophysiology of Haemostasis and Thrombosis, Vol.29, Iss.1, 2004-11, pp. : 48-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Challenges and Perspectives in Treating Adolescent and Young Adult Patients with Hematological Malignancies

By  

Acta Haematologica, Vol. 132, Iss. 3-4, 2014-09 ,pp. : 263-263

Karger

Access to resources Recommend Favorite

Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban

By  

ACADEMIC EMERGENCY MEDICINE, Vol. 22, Iss. 7, 2015-07 ,pp. : 796-802

John Wiley & Sons Inc

Access to resources Recommend Favorite

Etiology of specific molecular alterations in human malignancies

By  

Cytogenetic and Genome Research, Vol. 118, Iss. 2-4, 2007-11 ,pp. : 277-283

Karger

Access to resources Recommend Favorite

The Incidence and Risk Factors of Infusion-Related Reactions to Rituximab for Treating B Cell Malignancies in a Single Tertiary Hospital

By  

Oncology, Vol. 86, Iss. 3, 2014-01 ,pp. : 127-134

Karger

Access to resources Recommend Favorite

The Economic Impact of Treating Deep Vein Thrombosis with Low-Molecular-Weight Heparin: Outcome of Therapy and Health Economy Aspects

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 3, 2004-11 ,pp. : 8-16

Karger

Access to resources Recommend Favorite